Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042-MedSci.cn

Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042

Wu, YL; Zhang, L; Fan, Y; Zhou, J; Zhang, L; Zhou, Q; Li, W; Hu, C; Chen, G; Zhang, X; Zhou, C; Arenas, CG; Chen, Z; Yu, WC; Mok, TSK

JOURNAL OF THORACIC ONCOLOGY, 2023; 18 (4): S65

科室
- - 订阅+
  - 更多科室
工具
服务